Cardiology

1421-975114842023CardiologyCardiologyFeasibility of Patient-Managed ECG Recordings to Detect the Time of Atrial Fibrillation Recurrence after Electrical Cardioversion: Results from the PRE-ELECTRIC Study.347352347-35210.1159/000530304Electrical cardioversion (ECV) is a common procedure to terminate persistent atrial fibrillation (AF). The recurrence rate is high, and the patients often fail to recognize AF recurrence.The aim of the study was to evaluate the feasibility of patient-managed electrocardiography (ECG) to detect the time to AF recurrence after ECV.PRE-ELECTRIC (predictors for recurrence of atrial fibrillation after electrical cardioversion) is a prospective, observational study. Patients ≥18 years of age scheduled for ECV of persistent AF at Bærum Hospital were eligible for inclusion in the study. Time to recurrence of AF was detected by thumb ECG, recorded twice daily and whenever experiencing symptoms. The observation period was 28 days. We defined adherence as the observed number of days with ECG recordings divided by the expected number of days with ECG recordings. Study personnel contacted the participants by phone to assess their awareness of AF recurrence after a recurrence was detected in the thumb ECG.The study enrolled 200 patients scheduled for ECV of persistent AF at Bærum Hospital between 2018 and 2022. The mean age was 66.2 ± 9.3 years, and 21.0% (42/200) were women. The most frequent comorbidities were hypertension (n = 94, 47.0%) and heart failure (n = 51, 25.5%). A total of 164 participants underwent ECV of AF. The procedure was initially successful in 90.9%, of which 50.3% had a recurrence of AF within 4 weeks. The median time to recurrence was 5 days. Among the cardioverted participants, 123 (75.0%) had no missing days of thumb ECG recording during the observation period, and 97.0% had ≤3 missing days. More than a third (37.3%) of the participants with AF recurrence were unaware of the recurrence at the time of contact. Women were older and more symptomatic than men but had similar outcomes after ECV.Recurrence of AF after ECV was common. Using patient-managed thumb ECG was a feasible method to detect AF recurrence following ECV. Further studies are needed to investigate whether patient-managed ECG after ECV can optimize AF treatment.© 2023 The Author(s). Published by S. Karger AG, Basel.AndersenElizabeth LysterELInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.SolbergMagnar GangåsMGInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.Department of Internal Medicine, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.Walle-HansenMarte MeyerMMInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.EngerSteveSDepartment of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.OnarheimSophiaSDepartment of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.OlufsenMonaMDepartment of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.BergeTrygveTDepartment of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.Department of Internal Medicine, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.ChristophersenIngrid ElisabethIEDepartment of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.UlimoenSara ReinvikSRDepartment of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.TveitArnljotAInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.Department of Internal Medicine, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.engObservational StudyNews20230411

0884-04311972004JulJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral ResearchJ Bone Miner ResThe chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation.114411531144-53Chloride channel activity is essential for osteoclast function. Consequently, inhibition of the osteoclastic chloride channel should prevent bone resorption. Accordingly, we tested a chloride channel inhibitor on bone turnover and found that it inhibits bone resorption without affecting bone formation. This study indicates that chloride channel inhibitors are highly promising for treatment of osteoporosis.The chloride channel inhibitor, NS3736, blocked osteoclastic acidification and resorption in vitro with an IC50 value of 30 microM. When tested in the rat ovariectomy model for osteoporosis, daily treatment with 30 mg/kg orally protected bone strength and BMD by approximately 50% 6 weeks after surgery. Most interestingly, bone formation assessed by osteocalcin, mineral apposition rate, and mineralized surface index was not inhibited.Analysis of chloride channels in human osteoclasts revealed that ClC-7 and CLIC1 were highly expressed. Furthermore, by electrophysiology, we detected a volume-activated anion channel on human osteoclasts. Screening 50 different human tissues showed a broad expression for CLIC1 and a restricted immunoreactivity for ClC-7, appearing mainly in osteoclasts, ovaries, appendix, and Purkinje cells. This highly selective distribution predicts that inhibition of ClC-7 should specifically target osteoclasts in vivo. We suggest that NS3736 is inhibiting ClC-7, leading to a bone-specific effect in vivo.In conclusion, we show for the first time that chloride channel inhibitors can be used for prevention of ovariectomy-induced bone loss without impeding bone formation. We speculate that the coupling of bone resorption to bone formation is linked to the acidification of the resorption lacunae, thereby enabling compounds that directly interfere with this process to be able to positive uncouple this process resulting in a net bone gain.SchallerSophieSNordic Bioscience A/S, Herlev, Denmark.HenriksenKimKSveigaardChristinaCHeegaardAnne-MarieAMHélixNathalieNStahlhutMartinMOvejeroMaria CMCJohansenJens VJVSolbergHeleneHAndersenThomas LTLHougaardDoritDBerrymanMarkMShiødtChristine BCBSørensenBjørn HBHLichtenbergJensJChristophersenPallePFogedNiels TNTDelaisséJean-MarieJMEngsigMichael TMTKarsdalMorten AMAengJournal ArticleResearch Support, Non-U.S. Gov't20040301

Publications by authors named "Asbjoerg Solberg Christophersen"

Feasibility of Patient-Managed ECG Recordings to Detect the Time of Atrial Fibrillation Recurrence after Electrical Cardioversion: Results from the PRE-ELECTRIC Study.

The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation.